News: SOL Norway sovereign fund excludes three more firms from portfolio, page-35

First 35 Last

Share
Profile

Follow
Bob183

170 Posts.

15

18/02/19

22:35

Post #: 37477532
Share

Originally posted by madamswer: ↑

This is complete garbage.
The unrealised capital gains/(losses) do indeed flow through the income statement.
Otherwise the balance sheet would show the 'portfolio' at cost not financial assets at fair value.

If what I posted is garbage, then it is only because I was using the company's audited financial statements and the accompanying detailed notes as my reference source.

And those financial statements and accompanying detailed notes state that, besides for a few small items (i.e,. investments in investment properties (valued at $158m) and trading equities (worth 70m), unrealised capital gains/(losses) on the remainder of SOL's $4.3bn of Non-Current Assets do not flow through the Income Statement.

Instead, the changes in fair value of investments are matched by movements in the asset revaluation reserve account (for Investments in Associates and Long-Term Equity Investments), or not at all (Investments in Controlled Entities and Joint Operations/Joint Ventures).

Fee free to refer to the notes to the accounts to correct your misunderstanding, notably:

Note 8: Investments in Controlled Entities (i.e., NHC+ a few other small entities) - not recognised as individual investment; instead, "...assets and liabilities of each controlled entity are recognised in SOL's Statement of Financial Position", so no P&L impact on change in fair value of controlled entities

Note 9: Investments in Joint Operations and Joint Ventures (same accounting treatment as for Investments in Controlled Entities)

Note 10: Investments in Associates (Carrying Value @ 30 June 2018 = $1.517bn; Fair Value = $2.836bn) - Equity accounted. "Carrying value does not reflect the fair value of the Group's investment in the associates."

Note 11: Other Equity Investments (Carrying Value (reflected at fair value) of at $732m) - "Changes in the value of long-term equity investments are recognised in equity through the asset revaluation reserve...", i.e., not through the P&L.

Summary:

The only changes in asset fair values that are booked to SOL's P&L relate to SOL's "trading equities" and "investment properties". But, together, these represent only $230m, out of Total Assets of $5.3 billion, so quite insignificant in the scheme of things.

Expand

you are a wonderful poster, very thoughtful and intelligent
always easy to read

SOL Price at posting: $29.21 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

MTM

Australian Rare Earths bullish on early-stage uranium potential at Overland, SA

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

There are more pages in this discussion • 12 more messages in this thread...

First 35 Last

Add SOL (ASX) to my watchlist

(20min delay)
Last $34.91		Change 0.240(0.69%)		Mkt cap ! $12.41B

Open	High	Low	Value	Volume
$34.87	$35.03	$34.86	$1.661M	47.57K

Buyers (Bids)

No.	Vol.	Price($)
9	336	$34.91

Sellers (Offers)

Price($)	Vol.	No.
$34.93	634	8

View Market Depth

No.	Vol.	Price($)
1	2064	26.890
1	4429	26.870
2	5019	26.840
4	13889	26.820
1	153	26.810

Price($)	Vol.	No.
26.940	1229	1
26.950	4947	1
26.970	5993	2
26.990	4687	1
27.000	4408	1

Last trade - 12.18pm 28/11/2024 (20 minute delay)

SOL (ASX) Chart

News: SOL Norway sovereign fund excludes three more firms from portfolio, page-35

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Australian Rare Earths bullish on early-stage uranium potential at Overland, SA

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Buyers (Bids)

Sellers (Offers)